Armistice Capital, LLC Travere Therapeutics, Inc. Transaction History
Armistice Capital, LLC
- $7.08 Billion
- Q4 2024
A detailed history of Armistice Capital, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 7,358,000 shares of TVTX stock, worth $169 Million. This represents 1.81% of its overall portfolio holdings.
Number of Shares
7,358,000
Previous 7,648,000
3.79%
Holding current value
$169 Million
Previous $107 Million
19.8%
% of portfolio
1.81%
Previous 1.78%
Shares
15 transactions
Others Institutions Holding TVTX
# of Institutions
213Shares Held
94MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$175 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$154 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$114 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$97.6 Million0.09% of portfolio
-
Janus Henderson Group PLC London, X04.06MShares$93 Million0.04% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.47B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...